Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes treated with CSII at least 3 months.~* Males and females, \> 18 years but \< 75 years old.~* Hemoglobin A1c ≤ 8.0 % at measurement taken at week 0 (screening visit).~* Duration of diabetes ≥ 12 months.~* Willingness to perform self-blood glucose monitoring several times/day.~Exclusion Criteria:~* Previous insulin precipitation in pump infusion catheters.~* Daily insulin requirements \> 25% of pump reservoir capacity. (This would preclude the subject from using the pump infusion system for more than 3 days).~* Use of an insulin pump that does not have a downloadable record of basal and bolus doses.~* Known or suspected allergy to trial products.~* Pregnancy, breast-feeding, intention to become pregnant or inadequate contraception measures.~* Known or suspected alcohol or drug abuse.~* Impaired renal function with creatinine ≥ 1.7 mg/dl.~* Pronounced catheter site scarring.~* Chronic use of drugs that may influence glycemic control (e.g. steroids).~* Any other significant concomitant disease that would interfere with participation in and completion of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin Aspart Versus Insulin Lispro (Type: ACTIVE_COMPARATOR): Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
- Insulin Lispro Versus Insulin Aspart (Type: ACTIVE_COMPARATOR): Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).

Based on this trial design, predict the completion outcome and termination type (if applicable).